Evidence map›Paper›PMID 31200501›Full record

ArticlePharmaceutics2019

Fused Deposition Modeling 3D Printing: Test Platforms for Evaluating Post-Fabrication Chemical Modifications and In-Vitro Biological Properties.

Petra Arany, Eszter Róka, Laurent Mollet, Anthony W Coleman, Florent Perret, Beomjoon Kim, Renátó Kovács, Adrienn Kazsoki, Romána Zelkó, Rudolf Gesztelyi and 6 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Petra AranyDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. arany.petra@pharm.unideb.hu.
Eszter RókaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. eszter.roka@gmail.com.ORCID 0000-0003-1699-7143
Laurent MolletLMI CNRS UMR 5615, Université Lyon 1, 69622 Villeurbanne, France. laurent.mollet@univ-lyon1.fr.ORCID 0000-0002-4732-1069
Anthony W ColemanLMI CNRS UMR 5615, Université Lyon 1, 69622 Villeurbanne, France. anthony.coleman@univ-lyon1.fr.
Florent PerretICBMS, UMR 5246, Université Lyon 1, F69622 Villeurbanne, France. florent.perret@univ-lyon1.fr.ORCID 0000-0003-1413-6374
Beomjoon KimLIMMS/CNRS-IIS UMI 2820, Institute of Industrial Science, The University of Tokyo, Tokyo 153-8505, Japan. bjoonkim@iis.u-tokyo.ac.jp.ORCID 0000-0001-9565-299X
Renátó KovácsDepartment of Medical Microbiology, Faculty of Medicine and Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. kovacs.renato@med.unideb.hu.
Adrienn KazsokiUniversity Pharmacy Department of Pharmacy Administration, Faculty of Pharmacy, University of Semmelweis, Hőgyes Endre utca 7-9, H-1092 Budapest, Hungary. kazsoki.adrienn@pharma.semmelweis-univ.hu.
Romána ZelkóUniversity Pharmacy Department of Pharmacy Administration, Faculty of Pharmacy, University of Semmelweis, Hőgyes Endre utca 7-9, H-1092 Budapest, Hungary. zelko.romana@pharma.semmelweis-univ.hu.ORCID 0000-0002-5419-9137
Rudolf GesztelyiDepartment of Pharmacology and Pharmacotherapy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. gesztelyi.rudolf@pharm.unideb.hu.ORCID 0000-0001-7911-055X
Zoltán UjhelyiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. ujhelyi.zoltan@pharm.unideb.hu.
Pálma FehérDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. feher.palma@pharm.unideb.hu.
Judit VáradiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. varadi.judit@pharm.unideb.hu.
Ferenc FenyvesiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. fenyvesi.ferenc@pharm.unideb.hu.
Miklós VecsernyésDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. vecsernyes.miklos@pharm.unideb.hu.
Ildikó BácskayDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, H-4032 Debrecen, Hungary. bacskay.ildiko@pharm.unideb.hu.
University of Debrecen · HUUniversité Claude Bernard Lyon 1 · FRSemmelweis University · HUCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

3D printing is attracting considerable interest for its capacity to produce prototypes and small production runs rapidly. Fused deposit modeling (FDM) was used to produce polyvalent test plates for investigation of the physical, chemical, and in-vitro biological properties of printed materials. The polyvalent test plates (PVTPs) are poly-lactic acid cylinders, 14 mm in diameter and 3 mm in height. The polymer ester backbone was surface modified by a series of ramified and linear oligoamines to increase its hydrophilicity and introduce a positive charge. The chemical modification was verified by FT-IR spectroscopy, showing the introduction of amide and amine functions, and contact angle measurements confirmed increased hydrophilicity. Morphology studies (SEM, optical microscopy) indicated that the modification of PVTP possessed a planar morphology with small pits. Positron annihilation lifetime spectroscopy demonstrated that the polymeric free volume decreased on modification. An MTT-based prolonged cytotoxicity test using Caco-2 cells showed that the PVTPs are non-toxic at the cellular level. The presence of surface oligoamines on the PVTPs reduced biofilm formation by

Indexed as

biofilm formationchemical modificationfused deposition modelingMTT assaypolylactic acid

Identifiers

PMID31200501
PMCPMC6630791
OpenAlexW2950675893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.